Pfizer Inc.'s
fourth-quarter earnings soared as the pharmaceutical giant
benefited from a gain on the pending sale of its nutrition business and lower
acquisition-related charges and other items
For the year, the company projected per-share earnings of $2.20 to $2.30 on
revenue of $56.2 billion to $58.2 billion
Analysts polled by Thomson Reuters
recently expected $2.29 and $57.56 billion, respectively
Pfizer's animal-medicine business is set to go public on Friday in what would
be the largest deal from a U.S. company since Facebook Inc.'s (FB) IPO last May
The animal-health business, which has been dubbed Zoetis Inc., is aiming to
raise as much as $2.2 billion in its market debut
The coming IPO is part of
Pfizer's plan to shed certain businesses and hone its focus on human
pharmaceuticals, partially unwinding years of megamergers that made Pfizer the
largest drug maker in the world by sales
Pfizer previously agreed to sell its
nutrition unit to Nestle SA for $11.85 billion in cash
Pfizer reported a profit of $6.32 billion, or 85 cents a share, up from $1.44
billion, or 19 cents a share, a year earlier
The latest period included a
per-share contribution of 66 cents from the nutrition business
Excluding
restructuring and acquisition-related charges and other items, adjusted earnings
from continuing operations were down at 47 cents from 49 cents
Revenue
decreased 6.6% to $15.07 billion
Analysts polled by Thomson Reuters most recently projected earnings of 44
cents on revenue of $14.38 billion
U.S. revenue declined 9%, mostly on the loss of exclusivity of Lipitor in
November 2011 and Geodon in March 2012
Biopharmaceutical segment sales declined 8.8%, offsetting animal-health sales
growth of 5.9% and consumer health-care segment sales improvement of 16%
Welcome
Billie, with academic training in Fundamental Mathematics and professional experience in Large Multinationals in the Information Technology sector, having held positions in high-level management positions, maintains that it is time to reduce Unproductive Public Expenditure and help the Private Sector in everything that is possible.
Cortesía de Investing.com
Agenda Macro
Calendario económico en tiempo real proporcionado por Investing.com España.
No hay comentarios:
Publicar un comentario